GlassScriptPhysician profile
Harry L Mcdaris
NPI 1265499099
$306,686.40
in general payments reported to CMS, 2019-2025
22 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $87K · 2021: $65K · 2022: $33K · 2023: $8,641 · 2024: $8,864 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $3,924 · Food and Beverage: $3,530 · Travel and Lodging: $297 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,043.75 |
| Consulting Fee | $3,924.00 |
| Food and Beverage | $3,530.18 |
| Travel and Lodging | $297.01 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71,693.00 | 2021-2025 | |
| Lilly USA, LLC | $62,812.96 | 2019-2023 | Emgality |
| Allergan, INC. | $56,057.17 | 2019-2021 | |
| Amgen INC. | $55,121.93 | 2019-2023 | Aimovig |
| Pfizer INC. | $16,503.27 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $15,591.83 | 2019-2025 | Ajovy, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $13,526.74 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,785.28 | 2022 | |
| Impel Pharmaceuticals INC. | $3,710.98 | 2022-2023 | Trudhesa |
| Promius Pharma LLC | $1,019.98 | 2019 | |
| Supernus Pharmaceuticals, INC. | $785.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $552.58 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $533.87 | 2019-2022 | |
| Lundbeck LLC | $466.91 | 2020-2025 | Vyepti |
| Impel Pharmaceuticals LLC | $153.18 | 2025 | Trudhesa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $137.46 | 2021-2024 | Onzetra Xsail, Contrave |
| Scilex Pharmaceuticals INC. | $92.08 | 2023 | Ztlido |
| Axsome Therapeutics, INC. | $59.24 | 2025 | Symbravo |
| Collegium Pharmaceutical, INC. | $30.65 | 2022 | |
| Tonix Medicines, INC. | $22.86 | 2025 | Zembrace Symtouch |
| Assertio Therapeutics, INC. | $16.24 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Mcdaris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.